Biomarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Oversold Stocks with Big RSI Rebound Potential
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. One of the most popular technical indicators for helping investors find these is the Relative Strength Index (RSI).
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BMRN or MYGN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)
BioMarin (BMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ascendis Challenges BioMarin, But Market Response Seems Excessive
Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo, but offers once-weekly dosing, potentially improving patient adherence. The achondroplasia market is significant, with potential annual revenues approaching $1 billion, but competition may impact market share. Ascendis faces financial challenges, including a cash runway of approximately 15 months and a current ratio below 1.0.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Bet on These 5 Stocks With Upgraded Broker Ratings Right Now
Brokers have deeper insights into stocks and the macroeconomic backdrop. One must follow broker rating upgrades to pick stocks like WWW, BMRN, DDOG, PGR & KVYO.
